Jane Street
EIGR

Jane Street’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Jane Street’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-763
Closed -$190K – 11231
2022
Q1 		$190K Buy
+763
New +$121K ﹤0.01% 9068

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Jane Street's EIGR Position: Q1 2024 in Review

Jane Street sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 984 shares — an estimated $6.62K sold.

Jane Street first reported a position in EIGR in Q4 2018 and held it in 9 quarters. The position peaked at $474K in Q4 2021. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Jane Street reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Jane Street sold 984 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $6.62K.
  • Jane Street first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2018 and held it in 9 quarters.
  • Jane Street's Eiger BioPharmaceuticals, Inc. position peaked at $474K in Q4 2021.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Jane Street's 13F filing for Q1 2024, filed 16 May 2024.